AnaptysBio Inc (ANAB)
19.00
-1.17
(-5.80%)
USD |
NASDAQ |
Nov 15, 16:00
18.02
-0.98
(-5.16%)
After-Hours: 20:00
AnaptysBio Research and Development Expense (TTM): 154.78M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 154.78M |
| June 30, 2024 | 143.44M |
| March 31, 2024 | 134.37M |
| December 31, 2023 | 132.28M |
| September 30, 2023 | 122.13M |
| June 30, 2023 | 113.32M |
| March 31, 2023 | 101.24M |
| December 31, 2022 | 88.80M |
| September 30, 2022 | 92.20M |
| June 30, 2022 | 92.36M |
| March 31, 2022 | 96.83M |
| December 31, 2021 | 98.50M |
| September 30, 2021 | 93.29M |
| June 30, 2021 | 90.61M |
| March 31, 2021 | 83.24M |
| December 31, 2020 | 80.02M |
| September 30, 2020 | 79.88M |
| June 30, 2020 | 90.27M |
| March 31, 2020 | 99.68M |
| Date | Value |
|---|---|
| December 31, 2019 | 99.34M |
| September 30, 2019 | 93.83M |
| June 30, 2019 | 81.78M |
| March 31, 2019 | 65.02M |
| December 31, 2018 | 56.20M |
| September 30, 2018 | 47.88M |
| June 30, 2018 | 36.70M |
| March 31, 2018 | 33.32M |
| December 31, 2017 | 29.44M |
| September 30, 2017 | 26.85M |
| June 30, 2017 | 23.44M |
| March 31, 2017 | 18.57M |
| December 31, 2016 | 15.42M |
| September 30, 2016 | 16.98M |
| June 30, 2016 | 18.04M |
| March 31, 2016 | 19.03M |
| December 31, 2015 | 17.30M |
| September 30, 2015 | 13.34M |
| June 30, 2015 | 11.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
79.88M
Minimum
Sep 2020
154.78M
Maximum
Sep 2024
104.33M
Average
97.66M
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| Regeneron Pharmaceuticals Inc | 4.897B |
| Ligand Pharmaceuticals Inc | 22.49M |
| Agios Pharmaceuticals Inc | 295.96M |
| ADMA Biologics Inc | 1.868M |